0LB2 Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0LB2 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Supernus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.59 |
| 52 Week High | US$40.45 |
| 52 Week Low | US$25.81 |
| Beta | 0.90 |
| 1 Month Change | 3.31% |
| 3 Month Change | 9.91% |
| 1 Year Change | 42.33% |
| 3 Year Change | 33.34% |
| 5 Year Change | 62.59% |
| Change since IPO | -4.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0LB2 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 2.7% | 0.7% | 0.3% |
| 1Y | 42.3% | 8.2% | 10.4% |
Return vs Industry: 0LB2 exceeded the UK Pharmaceuticals industry which returned 8.2% over the past year.
Return vs Market: 0LB2 exceeded the UK Market which returned 10.4% over the past year.
Price Volatility
| 0LB2 volatility | |
|---|---|
| 0LB2 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0LB2 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0LB2's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 652 | Jack Khattar | www.supernus.com |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.
Supernus Pharmaceuticals, Inc. Fundamentals Summary
| 0LB2 fundamental statistics | |
|---|---|
| Market cap | US$2.16b |
| Earnings (TTM) | US$59.71m |
| Revenue (TTM) | US$651.97m |
36.2x
P/E Ratio3.3x
P/S RatioIs 0LB2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0LB2 income statement (TTM) | |
|---|---|
| Revenue | US$651.97m |
| Cost of Revenue | US$71.44m |
| Gross Profit | US$580.54m |
| Other Expenses | US$520.83m |
| Earnings | US$59.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 1.08 |
| Gross Margin | 89.04% |
| Net Profit Margin | 9.16% |
| Debt/Equity Ratio | 0% |
How did 0LB2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/15 13:54 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Supernus Pharmaceuticals, Inc. is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emily Bodnar | Berenberg |
| David Buck | B. Riley Securities, Inc. |
| John Tanner | Cantor Fitzgerald & Co. |